Mereo Biopharma Share Discussion Threads

[showmethemoneyhoney01] 10/2/2020 21:33

Closed on nasdaq at exactly $2. 28% up. Let's see what tomorrow brings. They do seem to like their 12pm RNS's

[master rsi] 10/2/2020 15:27

Yes is doing much better than over here, still very volatile and the $2 mark is resistance so far

[leedslad001] 10/2/2020 15:17

Up 27% in us

[showmethemoneyhoney01] 10/2/2020 13:47

US pre market on Nasdeq up 46% atm

[showmethemoneyhoney01] 10/2/2020 13:32

Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "We are very pleased to have secured financing from both Novartis and Aspire, and we look forward to the continued advancement of our pipeline in 2020.

[costax1654x] 09/2/2020 23:50

https://www.google.co.uk/amp/s/slatersentinel.com/news/2020/02/05/insider-selling-mereo-biopharma-group-plc-lonmph-insider-sells-300000-shares-of-stock-updated-updated.html/amp

[sbb1x] 04/2/2020 13:32

Reversal on ?

[sbb1x] 03/2/2020 16:03

23p on the bid....When are the buyers coming in 19p ?

[costax1654x] 29/1/2020 14:44

As expected and seen on chart....soon below 20!

[master rsi] 28/1/2020 16:59

LSE
MPH 29p +3p +11.5%

On the Nasdag currently
MPHO 1.75 v 1.79 +0.2877 +019.2%

[showmethemoneyhoney01] 28/1/2020 13:12

A detailed overview of the company.

The Company's lead drug candidate is Setrusumab, a potential treatment for osteogenesis imperfecta, also known as brittle bone disease. Setrusumab was acquired from Novartis in 2015.

Osteogenesis imperfecta, or OI, is a rare genetic disorder characterized by bone fragility leading to fracture and bone deformity, chronic bone pain and reduced mobility. (Source: NCBI). An estimated 20,000 to 50,000 people in the United States have osteogenesis imperfecta, according to reports. To date, there are no approved treatments for OI.

In a phase IIb study, which evaluated Setrusumab in adults with Type I, III or IV osteogenesis imperfecta, dubbed ASTEROID, a trend of reduction in fractures was observed in the high dose cohort. The results of this study were reported last month.


The primary endpoint of the ASTEROID study was change in Trabecular Volumetric Bone Mineral Density (Tr vBMD) of the radius (wrist) over baseline after 12 months of treatment. However, this was not met but an increase in total vBMD at the wrist, a secondary endpoint of the study, was observed and reached statistical significance in the medium and high dose cohorts, according to the Company.

Despite the ASTEROID study not meeting the primary endpoint, the Company is confident of Setrusumab's potential and plans to advance the compound to a pediatric pivotal trial for the treatment of Osteogenesis Imperfecta.

Mereo's Paediatric Investigation Plan (PIP) has been approved by the European Medicines Agency and a study design has been agreed for a pivotal study in children with OI, based on a primary endpoint of fracture rate over a 12-month period.

The pivotal study will be conducted in approximately 165 children aged 5 to less than 18 years old, with OI, initially in EU and Canada, with potential expansion into the U.S. following planned discussions with the FDA. This pivotal trial has fractures and fracture reduction as its primary endpoint.


The other investigational drugs in the pipeline are:

-- MPH-966, (Alvelestat) an oral neutrophil elastase inhibitor, being explored for the potential treatment of alpha-1 antitrypsin deficiency (AATD), under a phase II study. Mereo expects to report top-line data from this study in mid-2020 and if the results are positive, will seek regulatory advice on the design of a pivotal trial. This compound was acquired from AstraZeneca in 2017.

-- Acumapimod, a phase III-ready compound, for Acute Exacerbations of Chronic Obstructive Pulmonary Disease, or AECOPD.

-- BGS-649 (leflutrozole) that has completed phase IIb development as a first-line therapy for the treatment of obese men with hypogonadotropic hypogonadism.


-- Navicixizumab (OMP-305B83), a phase II-ready compound, for Advanced Platinum-Resistant Ovarian Cancer.

-- Etigilimab, which has completed a phase 1a/b trial in advanced solid tumors.

The Company is seeking partnering opportunities for its compounds. As of June 30, 2019, Mereo had cash of £36.1 million.

Mereo BioPharma is the result of the merger between NASDAQ-listed OncoMed and London Stock Exchange's AIM market-listed Mereo BioPharma, the combination of which was completed in April 2019. The combined company is dual-listed on the NASDAQ and AIM market.

[master rsi] 28/1/2020 13:01

Nasdag quote once it opens

[showmethemoneyhoney01] 28/1/2020 12:52

Talking to several interesting parties in funding the final phase of the brittle bone medication. Announcement due anytime. The royalties could be huge on something unique like this. Amazing we are at these levels considering that they only recently announced another free carry to development licencing deal recently.

[master rsi] 28/1/2020 12:51

a nice 40K buy paying 30.80p after being marked down due to 2 small sells of 6K and 7K

[ny boy] 28/1/2020 12:46

Bubbling away nicely, rocket status this quarter, a definite hold for me Sir!

[master rsi] 28/1/2020 12:21

Spiking now as all are buys even the large size ones

[showmethemoneyhoney01] 28/1/2020 12:19

Up over 20% on less than £100k of buys.

[master rsi] 28/1/2020 12:13

More clear is water, but the 5 days chart say more than a cheap coffee at "Costas"

[master rsi] 28/1/2020 12:11

Wrong place to buy COFFEE ... Costas

The Greeks are long gone without Onassis

[costax1654x] 28/1/2020 12:07

Will be nice over 40

[showmethemoneyhoney01] 28/1/2020 12:06

Plus it is NT for just 2,000 shares atm. Go figure